Active substances: Norfloxacin
Multivitamins, products containing iron or zinc, antacids or sucralfate should not be taken at the same time as this medicine.
This medicine should be taken either 2 hours before or at least 4 hours after such products.
Pregnancy, breast-feeding and fertility If you are pregnant, planning a family or breast-feeding, tell your doctor before taking this medicine, as it is not recommended for use under these conditions. How to take Norfloxacin 400 mg Always take your medicine exactly as your doctor or Pharmacist has told you.Do not pass it on to. This includes any possible side effects others.
You should check with your doctor or pharmacist if you are not sure. The usual dose in adults is 1 film-coated tablet 400 mg norfloxacin twice daily.
The recommended dose is 1 film-coated tablet 400 mg norfloxacin once daily. Swallow the tablets with a glass of water at least one hour before or two hours after a meal or drink of milk.
Preferably the tablets should be taken in the morning and evening. If you only take a single daily dose, always take this at the same time of day. The duration of treatment depends on the type and severity of infection.
For women with acute, uncomplicated inflammation of the bladder, the usual duration of treatment is a 3 day course of this medicine with the recommended dose.
In the treatment of urinary tract infections, adults will generally need to use this medicine for 7-10 days. In chronic inflammation of the prostate the usual duration of treatment is 4 weeks.
The symptoms of urinary tract infection, such as a burning sensation experienced during passing water, pain, and fever, will generally disappear within 1-2 days.
However, the treatment course with this medicine should be continued for up to 12 weeks in chronic relapsing urinary tract infections. Ciprofloxacin is being licensed for the treatment of Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli and Inhalational Anthrax post-exposure and levofloxacin was recently licensed for the treatment of Inhalational Anthrax post-exposure.
However, the Fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK. Adverse effects In general, fluoroquinolones are well tolerated, with most side-effects being mild to moderate.
The overall rate of adverse events in patients treated with fluoroquinolones is roughly similar to that seen in patients treated with other antibiotic classes.
Centers for Disease Control study found patients treated with fluoroquinolones experienced adverse events severe enough to lead to an emergency department visit more frequently than those treated with cephalosporins or macrolides, but less frequently than those treated with penicillins, clindamycin, sulfonamides, or vancomycin.
Among these, tendon problems and exacerbation of the symptoms of the neurological disorder myasthenia gravis are the subject of "black box" warnings in the United States.
Younger people typically experience good recovery, but permanent disability is possible, and is more likely in older patients.
Simultaneous use of corticosteroids is present in almost one-third of quinolone-associated tendon rupture. At 28 d significant levels of flumequine were present in liver, kidney and skin with traces in muscle, and at the last sampling point 56 d in eye, bone, bile and posterior intestine.
Traces were present in skin and eye over 7 d.
The maximal flumequine concentrations in blood were calculated to be 2. A summary follows of the Committee's evaluations of toxicological and residue data on a variety of veterinary drugs: one anthelminthic agent ivermectin; four antimicrobial agents flumequine, lincomycin, oxytetracycline and tilmicosin; six insecticides cyhalothrin, cypermethrin, alpha-cypermethrin, dicyclanil, permethrin and metrifonate trichlorfon; and one production aid melengestrol acetate.
Annexed to the report are a summary of the Committee's recommendations on these drugs, including Acceptable Daily Intakes and Maximum Residue Limits and further information required.